TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32081989

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Skylights headset
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (no VR)
Number of subjects: 50
Study: 33942338

Group type: EXPERIMENTAL
Intervention: Mann‐Whitney probability estimation procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence interval estimation procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variance estimators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logit and inverse hyperbolic sine transformations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster randomization trials
Number of subjects: 0
Study: 33243018

Group type: EXPERIMENTAL
Intervention: Quxie capsule (QX) treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study: 35985551

Group type: EXPERIMENTAL
Intervention: Video visits
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 653
Study: 34470831

Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg biweekly, total 2 g over 40 weeks)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ferric carboxymaltose (500 mg every 10 weeks, total 2 g over 40 weeks)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ferric carboxymaltose
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agent use
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 142
Study: 35766224

Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inotersen (greatest-benefit subgroup)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (greatest-benefit subgroup)
Number of subjects: 0
Study: 33529612

Group type: EXPERIMENTAL
Intervention: Activity-based home program
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Exercise-based home program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 33774620

Group type: EXPERIMENTAL
Intervention: Water supplementation in habitual low drinkers with high copeptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water supplementation for 1 year
Number of subjects: 0
Study: 34965603

Group type: EXPERIMENTAL
Intervention: Absorbable nasal implant
Number of subjects: 111
Study: 32318809

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily for 7 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fedratinib 500 mg single dose
Number of subjects: 26
Study: 36227659

Group type: EXPERIMENTAL
Intervention: mPEG-HA-Pt treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional chemotherapy (control)
Number of subjects: 76
Study: 34510143

Group type: EXPERIMENTAL
Intervention: Prismatic RGP contact lenses with a base-down prism of 1.6 prism diopters
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard rigid-gas-permeable contact lenses
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both contact lens designs (standard and prismatic)
Number of subjects: 17
Study: 32400321

Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Number of subjects: 60
Study: 35114286

Group type: EXPERIMENTAL
Intervention: Instant coffee with 3 mg/kg caffeine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Instant coffee with 6 mg/kg caffeine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study: 33122028

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 64
Study: 33747510

Group type: EXPERIMENTAL
Intervention: Ligelizumab (240 mg q2w)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study: 36315560

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 152
Study: 33779577

Group type: EXPERIMENTAL
Intervention: Generic escitalopram
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Proprietary escitalopram (Lexapro)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 35727573

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (10 billion CFUs daily during antibiotic treatment and for 7 days after)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 350
Study: 33125674

Group type: EXPERIMENTAL
Intervention: Globalagliatin (high-dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 36096108

Group type: EXPERIMENTAL
Intervention: Hemodialysis + Hemoperfusion (HD + HP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Simple Hemodialysis (HD)
Number of subjects: 150
Study: 33210331

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no eating disorder)
Number of subjects: 10
Study: 35762272

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32124728

Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with aluminum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with AS01E
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with AS03B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 4 μg/serotype/dose adjuvanted with aluminum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36351688

Group type: EXPERIMENTAL
Intervention: Immediate radiographer (IR) reporting
Number of subjects: 8682

Group type: COMPARATOR
Intervention: Standard radiographer (SR) reporting
Number of subjects: 8682
Study: 33664127

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC=6 every 3 weeks for six cycles)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Adjuvant concurrent chemoradiotherapy (whole pelvis irradiation 50.4 Gy and cisplatin 40 mg/m2/week)
Number of subjects: 250
Study: 32951642

Group type: EXPERIMENTAL
Intervention: TEDR repair for tears >3 cm
Number of subjects: 80

Group type: COMPARATOR
Intervention: SR repair for tears >3 cm
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SR repair for tears <3 cm
Number of subjects: 80

Group type: COMPARATOR
Intervention: TEDR repair for tears <3 cm
Number of subjects: 80
Study: 35631319

Group type: EXPERIMENTAL
Intervention: Multifactorial diet
Number of subjects: 37

Group type: COMPARATOR
Intervention: MUFA diet
Number of subjects: 37
Study: 34237597

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-Daikenchuto (non-DKT)
Number of subjects: 17
Study: 33551282

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1232
Study: 34749319

Group type: EXPERIMENTAL
Intervention: Low-intensity magnetic laser therapy (LLLT)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic stimulation
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 154
Study: 33683381

Group type: EXPERIMENTAL
Intervention: Pelvic reconstruction with postoperative infection
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pelvic fracture fixation (control group)
Number of subjects: 18
Study: 34682668

Group type: EXPERIMENTAL
Intervention: E-Fit (home-based exercise intervention)
Number of subjects: 40
Study: 32666240

Group type: EXPERIMENTAL
Intervention: Locking Compression Plate (LCP) fixation (group 1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Interlocking Nail (ILN) (group 2)
Number of subjects: 63
Study: 34115544

Group type: EXPERIMENTAL
Intervention: Genomic ALK amplification (ALKa)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Clonal ALK mutations (ALKm)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Subclonal ALK mutations (ALKm)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: No ALK alterations
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: More than one metastatic compartment
Number of subjects: 1092
Study: 32999058

Group type: EXPERIMENTAL
Intervention: Home-based motor training telerehabilitation (TR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 52
Study: 33753870

Group type: EXPERIMENTAL
Intervention: Vigil-1st (Vigil first)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atezo-1st (Atezolizumab first)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigil-1st
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atezo-1st
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigil-1st (in BRCAwt subset)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atezo-1st (in BRCAwt subset)
Number of subjects: 24
Study: 33549606

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 42
Study: 35011083

Group type: EXPERIMENTAL
Intervention: 600 mg of WHS
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 93
Study: 34914845

Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program (SSP) - 4 weekly sessions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) - CBT-I referral plus sleep hygiene handout
Number of subjects: 40
Study: 32338543

Group type: EXPERIMENTAL
Intervention: Approach bias modification (six sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study: 33570130

Group type: EXPERIMENTAL
Intervention: Negative control outcomes in Mendelian randomization studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative control outcomes in MR studies
Number of subjects: 0
Study: 32464838

Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 11185

Group type: COMPARATOR
Intervention: Sternotomy
Number of subjects: 11185
Study: 34103434

Group type: EXPERIMENTAL
Intervention: Thrombodynamics test in addition to local coagulation tests (LCT)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Local coagulation tests (LCT)
Number of subjects: 245
Study: 35090365

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Physical Education (PE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 52
Study: 32873406

Group type: EXPERIMENTAL
Intervention: Hong Kong strain vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Saitama strain vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both vaccines against A/Osaka/188/2017
Number of subjects: 100
Study: 35606707

Group type: EXPERIMENTAL
Intervention: Single-step transepithelial photorefractive keratectomy (TPRK)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Off-flap epipolis-laser in situ keratomileusis (Epi-LASIK)
Number of subjects: 32
Study: 32994091

Group type: EXPERIMENTAL
Intervention: Concomitant metformin
Number of subjects: 486

Group type: COMPARATOR
Intervention: No concomitant metformin
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Concomitant sulfonamide-based α1-receptor blockers
Number of subjects: 486

Group type: COMPARATOR
Intervention: No concomitant sulfonamide-based α1-receptor blockers
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Concomitant quinazoline-based α1-receptor blockers
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: All other medication classes
Number of subjects: 486
Study: 34529913

Group type: EXPERIMENTAL
Intervention: 1% H2O2 for gargling, 0.5% H2O2 for nasal wash (experimental group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 100
Study: 34743666

Group type: EXPERIMENTAL
Intervention: Switch to dolutegravir 50 mg once daily for 120 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remain on raltegravir 400 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 32998932

Group type: EXPERIMENTAL
Intervention: Single postoperative dose of zoledronic acid
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 35321778

Group type: EXPERIMENTAL
Intervention: tACS (0.75 mA, 0.75 Hz, 5-minute)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no tACS)
Number of subjects: 9
Study: 33340259

Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion program (MAC-P)
Number of subjects: 18
Study: 32423006

Group type: EXPERIMENTAL
Intervention: Game-group (serious game intervention)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-game-group (control)
Number of subjects: 14
Study: 34662180

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 191

Group type: COMPARATOR
Intervention: CISGEM
Number of subjects: 191
Study: 34963666

Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 79
Study: 35678882

Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron supplementation (30 mg daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No supplementation to ESA treatment (Control group)
Number of subjects: 60
Study: 32179149

Group type: EXPERIMENTAL
Intervention: Colistin loading dose (LD group) of 4 mg of colistin base activity (CBA)/kg/dose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard initial dose (NLD group) of 2.5 mg (12‐h interval) or 1.7 mg (8‐h interval) of CBA/kg/dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (LD and NLD)
Number of subjects: 20
Study: 36343166

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 56

Group type: COMPARATOR
Intervention: MT-DSAEK
Number of subjects: 56
Study: 34741629

Group type: EXPERIMENTAL
Intervention: Small IMN (10 mm in males, 9 mm in females)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Large IMN (12 mm in males, 11 mm in females)
Number of subjects: 60
Study: 34187482

Group type: EXPERIMENTAL
Intervention: CleanCook stove and ethanol fuel
Number of subjects: 324

Group type: COMPARATOR
Intervention: Firewood/kerosene (control group)
Number of subjects: 324
Study: 35318290

Group type: EXPERIMENTAL
Intervention: Immediate implants (Group I)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Delayed implants (Group II)
Number of subjects: 84
Study: 35150446

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34523115

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy (mostly clopidogrel) following 12 months of DAPT
Number of subjects: 498

Group type: COMPARATOR
Intervention: Complex PCI
Number of subjects: 498
Study: 33636517

Group type: EXPERIMENTAL
Intervention: Factors associated with PTSD
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Factors associated with depressive symptoms
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Overall mental health outcomes
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Impact of stigma and financial distress
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Potential interventions
Number of subjects: 542
Study: 35357957

Group type: EXPERIMENTAL
Intervention: Synchronous Telehealth Yoga
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Group Therapies
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 200
Study: 33801295

Group type: EXPERIMENTAL
Intervention: EMG-triggered robotic rehabilitation device treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lower limb rotor exercises (Control)
Number of subjects: 60
Study: 32702848

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Remifentanil (group R)
Number of subjects: 74
Study: 35863995

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB) with continuous infusion of bupivacaine 0.1% at 7 mL/h for 24 hours
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (Group M) received intravenous morphine patient controlled analgesia for 24 hours
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Number of subjects: 35
Study: 32649388

Group type: EXPERIMENTAL
Intervention: Lid hygiene
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daily disposable contact lens (DDCL) fitting (delefilcon A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Artificial tear (Povidone‐2%) supplementation
Number of subjects: 42
Study: 34543425

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 International Units per day)
Number of subjects: 161
Study: 33199752

Group type: EXPERIMENTAL
Intervention: PM-EE 600 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 34363528

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 371

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 371
Study: 32872000

Group type: EXPERIMENTAL
Intervention: Goreisan (7.5 g/d for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (no Kampo medicine)
Number of subjects: 0
Study: 34734262

Group type: EXPERIMENTAL
Intervention: Higher egg consumption (4th quartile, equivalent to 5-6 eggs per week)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Higher egg consumption (4th quartile)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Higher egg consumption
Number of subjects: 728
Study: 33642357

Group type: EXPERIMENTAL
Intervention: Drotaverine (80 mg three times a day, 1 hour before meals)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mebeverine (135 mg three times a day, 1 hour before meals)
Number of subjects: 200
Study: 32823413

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment (Group B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No anti-VEGF treatment (Group A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anti-VEGF monotherapy
Number of subjects: 12
Study: 36031115

Group type: EXPERIMENTAL
Intervention: High dose (HD) stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Shuffle programming (algorithmic adaptive conventional stimulation)
Number of subjects: 12
Study: 32776244

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg once daily for 6 months
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no α-blockers)
Number of subjects: 108
Study: 35073298

Group type: EXPERIMENTAL
Intervention: Cold therapy to hands and feet during chemotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care (no cold therapy)
Number of subjects: 48
Study: 33853807

Group type: EXPERIMENTAL
Intervention: Minimally invasive thoracoscopically guided right minithoracotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional sternotomy
Number of subjects: 0
Study: 34590543

Group type: EXPERIMENTAL
Intervention: F(ab’)2AV
Number of subjects: 21

Group type: COMPARATOR
Intervention: FabAV
Number of subjects: 21
Study: 32329198

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied with GaAlAs laser (808 nm, avg. power density: 50 mW, 66 J total dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 44
Study: 35993547

Group type: EXPERIMENTAL
Intervention: Bayesian Time Machine (time-adjusted analyses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian Time Machine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent or pooled controls
Number of subjects: 0
Study: 33470693

Group type: EXPERIMENTAL
Intervention: MAP thresholds of ≤60 mmHg
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: MAP thresholds of ≤55 mmHg
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: MAP thresholds of 65 mmHg or above
Number of subjects: 1018
Study: 34534138

Group type: EXPERIMENTAL
Intervention: DTG + 3TC
Number of subjects: 1433

Group type: COMPARATOR
Intervention: DTG + TDF/FTC
Number of subjects: 1433
Study: 32789901

Group type: EXPERIMENTAL
Intervention: Self-practice/self-reflection (SP/SR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitive behaviour therapy (CBT) book study
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitive behaviour therapy (CBT) training without SP/SR
Number of subjects: 29
Study: 33715993

Group type: EXPERIMENTAL
Intervention: Home spirometry with symptom tracking
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 267
Study: 34016732

Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA 6.0 GBq
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA 7.4 GBq
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PSA decline ≥ 50%
Number of subjects: 43
Study: 35341432

Group type: EXPERIMENTAL
Intervention: Controller medications adherence
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Oral steroid bursts
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Caregiver asthma QoL total score
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Caregiver asthma QoL activity limitations
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Caregiver asthma QoL emotional functioning
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Acute healthcare visits
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Asthma control
Number of subjects: 94
Study: 35291405

Group type: COMPARATOR
Intervention: Ropivacaine (5 cc of 0.25% solution)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ropivacaine (5 cc of 0.25% solution) plus dexmedetomidine (0.5 µg/kg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (Ropivacaine only)
Number of subjects: 74
Study: 35057479

Group type: EXPERIMENTAL
Intervention: Pork dry-cured ham (n = 35)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cooked ham (placebo group; n = 19)
Number of subjects: 54
Study: 33216756

Group type: EXPERIMENTAL
Intervention: Moving condition (VR visual feedback with a moving virtual hand)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hidden condition (no virtual hand)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Static condition (static virtual hand)
Number of subjects: 30